https://www.selleckchem.com/pr....oducts/tolebrutinib-
Resection was by hepatectomy with three studies reporting an R0 rate of 100%, 24% and 63%, respectively. Three studies reported histopathological evidence of prior treatment response. There were two treatment related deaths at 90 days. Median survival was 19 (95% CI 9.9-28) months and 5-year survival 20%. CONCLUSIONS There are potential benefits of treatment on both R0 rate and complete response in resected specimens. Scientific equipoise exists in relation to neoadjuvant chemoradiotherapy for PH-CCA. V.PURPOSE The purpos
Like
Comment
Share
